2-[4-[(1Z)-1,2-Diphenyl-1-buten-1-yl]phenoxy]-N-methylethanamine (Z)-2-(4-(1,2-二苯基丁-1-烯-1-基)苯氧基)-N-甲基乙胺
CAS 31750-48-8 MFCD31750488
化学结构图
SMILES:
化学属性
| Mol. Weight | 357.53 |
|---|---|
| Mol. Formula | C25H28ClNO |
别名和识别编码
| Chemical Name | 2-[4-[(1Z)-1,2-Diphenyl-1-buten-1-yl]phenoxy]-N-methylethanamine |
|---|---|
| Synonym | N-Desmethyltamoxifen ICI 55,548 Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N-methyl-, (Z)- Desmethyltamoxifen cis-2-(p-(1,2-Diphenyl-1-butenyl)phenoxy)-N-methylethylamine |
| CAS Number | 31750-48-8 |
| Chemicalbook ID | CB2267847 |
| Chemical Name Translation | (Z)-2-(4-(1,2-二苯基丁-1-烯-1-基)苯氧基)-N-甲基乙胺 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
相关文献及参考
- [2]. Morad SA, et al. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics. Biochim Biophys Acta. 2015 Jul;1851(7):919-28.
- [3]. Reddel RR,et al. N-desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in vitro. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1179-81.
- [4]. Seong Hwan Kim,et al. Use of Antidepressants in Patients with Breast Cancer Taking Tamoxifen. J Breast Cancer. 2010 Dec;13(4):325-336.
- [1]. Vertosick FT Jr, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol. 1994;19(2):97-103.
- [1]. Vertosick FT Jr, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol. 1994;19(2):97-103.
- [2]. Morad SA, et al. Modification of sphingolipid metabolism by tamoxif
安全信息
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE : 50 ug/kg SEX/DURATION : female 4 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) REFERENCE : CTRRDO Cancer Treatment Reports. (Washington, DC) V.60-71, 1976-87. For publisher information, see JNCIEQ. Volume(issue)/page/year: 64,741,1980
